Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.

被引：0
|
作者：
Dong, Wei [1 ]
Zhang, Songyan [1 ]
Huo, Zhuoni [1 ]
Lu, Junrong [1 ]
Liu, Haishi [1 ]
Wang, Ping [1 ]
Zhang, Yubao [1 ]
机构：
[1] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16160
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma
    Bai, Zhenhua
    Yu, Xianhuan
    Tang, Qibin
    Zhang, Rui
    Shi, Xiangde
    Liu, Chao
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2024, 85 (07)
  • [2] Hepatic arterial infusion chemotherapy in combination with PD-1 inhibitor as conversion therapy in locally advanced, potentially resectable hepatocellular carcinoma: A phase II study
    Xu, Li
    Zhang, Yaojun
    Chen, Minshan
    Wang, Xiaohui
    Hou, Jingyu
    Zhou, Zhongguo
    JOURNAL OF HEPATOLOGY, 2021, 75 : S247 - S247
  • [3] Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
    Mei, Jie
    Tang, Yu-Hao
    Wei, Wei
    Shi, Ming
    Zheng, Lie
    Li, Shao-Hua
    Guo, Rong-Ping
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy in combination with lenvatinib and PD-1 inhibitors
    Guo, Wenbo
    Chen, Song
    Zhao, Lihua
    Wu, Zhiqiang
    Cai, Hongjie
    Wang, Fan
    Wu, Lijia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
    Li, Shaohua
    Mei, Jie
    Zhao, Rongce
    Zhou, Jing
    Wang, Qiaoxuan
    Lu, Lianghe
    Li, Jibin
    Zheng, Lie
    Wei, Wei
    Guo, Rongping
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [6] Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study
    Sun, Ruirui
    Gou, Yang
    Pan, Long
    He, Qiang
    Zhou, Yin
    Luo, Yi
    Wu, Chenrui
    Zhao, Yaowu
    Fu, Zixuan
    Huang, Ping
    CELLULAR ONCOLOGY, 2024,
  • [7] Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study
    Li, Ruixia
    Wang, Xiaohui
    Li, Hui
    Wang, Murong
    Wang, Juncheng
    Wang, Wei
    Zhou, Qunfang
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 1727 - 1740
  • [8] Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to HAIC
    An, Chao
    Fu, Yan
    Li, Wang
    Zuo, Mengxuan
    Wu, Peihong
    CANCER, 2023, 129 (14) : 2235 - 2244
  • [9] Correction to: Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study
    Ruirui Sun
    Yang Gou
    Long Pan
    Qiang He
    Yin Zhou
    Yi Luo
    Chenrui Wu
    Yaowu Zhao
    Zixuan Fu
    Ping Huang
    Cellular Oncology, 2024, 47 (6) : 2277 - 2278
  • [10] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
    Zhang, Yufeng
    Zhang, Haiyan
    Xu, Haoqian
    Wang, Ying
    Feng, Long
    Yi, Fengming
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
12345